Jemperli 500 mg Injection Jemperli contains Dostarlimab-gxly, a humanized monoclonal antibody directed against the programmed cell death protein 1 (PD-1) receptor. It blocks the interactions between PD-1 and its ligands, PD-L1 and PD-L2, thereby inhibiting PD-1 pathway-mediated suppression of the immune response, including anti-tumor T-cell activity. It is indicated for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer, as well as dMMR recurrent or advanced solid tumors that have progressed on or following prior treatment and who have no satisfactory alternative treatment options.